Heinemann, V., Andre, T., Bekaii-Saab, T., Cercek, A., Nakamura, Y., Raghav, K., … Tabernero, J. (2024). Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress). In ONCOLOGY RESEARCH AND TREATMENT (Vol. 47, pp. 60–60).

Heinemann, Volker, Thierry Andre, Tanios Bekaii-Saab, Andrea Cercek, Yoshiaki Nakamura, Kanwal Raghav, Salvatore Siena, et al. “Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress).” In ONCOLOGY RESEARCH AND TREATMENT, 47:60–60, 2024.

Heinemann V, Andre T, Bekaii-Saab T, Cercek A, Nakamura Y, Raghav K, et al. Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress). In: ONCOLOGY RESEARCH AND TREATMENT. 2024. p. 60–60.

Heinemann, Volker, et al. “Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress).” ONCOLOGY RESEARCH AND TREATMENT, vol. 47, 2024, pp. 60–60.

Heinemann V, Andre T, Bekaii-Saab T, Cercek A, Nakamura Y, Raghav K, Siena S, Strickler J, Van Cutsem E, Adelberg D, Ramos J, Yang S, Yoshino T, Tabernero J. Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress). ONCOLOGY RESEARCH AND TREATMENT. 2024. p. 60–60.